A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.

NCT03540524 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: GLPG2451 dose regimen A
DRUG: GLPG2451 dose regimen B
DRUG: GLPG2222
DRUG: GLPG2737

Sponsor

Lakefront Biotherapeutics NV